EXPRE-SON-REA : Expressive Own Names in Neurophysiologic Assessment of Comatose Patients (EXPRESONREA)
EXPRE-SON-REA : Expressive Versus Neutral Own Names in Neurophysiologic Prognosis Assessment of Intensive Care Unit Comatose Patients.
Evaluating the neurologic prognosis in disorders of consciousness (DOC) patients is still a crucial issue in intensive care units.
Neurophysiology allows the investigators to record cerebral responses of patients to auditory stimuli and in particularly to their own name. Numerous studies try to improve the relevance of the auditory stimuli used in this paradigm.
Here the investigators assess if the use of own name stimuli uttered by more expressive voices (for example smiling voices) modulates the cerebral responses recorded. They then correlate these cerebral responses to the neurologic prognosis at three months.
연구 개요
상세 설명
Late auditory evoked potentials (as P3 wave) are used in neurophysiology to assess the level of consciousness in DOC (disorder of consciousness) patients. The P3 wave, elicited by listening standard and deviant stimuli, corresponds to the activation of a frontoparietal network and is considered to reflect a cognitive attention task. Using the own name of the patient as deviant stimuli improve the ability to detect the P3 wave because of the particularly relevance of this stimulus for the patient. However the correlation of this P3 wave and neurologic prognosis is still imperfect and depends on the etiology of the DOC.
In human cognition, to identify the expressivity valence of a voice is essential. Neural processing of expressive voices involves more widespread brain areas than neutral voices processing.
Here the investigators assume that using own name stimuli uttered by more expressive voices (positive : smiling voice or negative : rough voice) should recruit more widespread brain areas and modulate the cerebral responses recorded. The investigators then evaluate if these cerebral responses are relevant markers of consciousness and correlate them to neurologic prognosis at three months.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Estelle Pruvost-Robieux, MD
- 전화번호: + 33 1 45 65 81 89
- 이메일: e.pruvost@ghu-paris.fr
연구 연락처 백업
- 이름: Martine Gavaret, Professor
- 전화번호: + 33 1 45 65 81 89
- 이메일: m.gavaret@ghu-paris.fr
연구 장소
-
-
-
Paris, 프랑스, 75014
- 모병
- GHU Paris Psychiatrie Neurosciences
-
연락하다:
- Estelle Pruvost-Robieux, MD
- 전화번호: +33 1 45 65 81 89
- 이메일: e.pruvost@ghu-paris.fr
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age over 18
- Disorder of consciousness defined as :
Glasgow coma scale < 8 or >8 but
- eyes opening to pain only
- No response to basic command
- Available neuro-imagery (CT-scan or MRI)
- Normal temperature (no fever or hypothermia)
- Normal blood pressure during neurophysiologic evaluation
- Given consent from relatives
Exclusion Criteria:
- Brain death
- Known deafness
- Severe sepsis uncontrolled during neurophysiologic evaluation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 해당 없음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Whole group
The whole group listen successively the 3 paradigms :
|
Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Positive predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices for the neuroprognosis at 3 months
기간: 3 months from DOC evaluation
|
Determination of the positive predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Negative predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
기간: 3 months from DOC evaluation
|
Determination of the negative predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Sensitivity of P3a responses occurences to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
기간: 3 months from DOC evaluation
|
Determination of the sensibility of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Specificity of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
기간: 3 months from DOC evaluation
|
Determination of the specificity of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
기간: 7, 14 and 28 days from DOC evaluation
|
Determination of the negative predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
기간: 7, 14 and 28 days from DOC evaluation
|
Determination of the positive predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to the CRS-r scale
기간: 7, 14 and 28 days from DOC evaluation
|
Determination of the sensibility of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
기간: 7, 14 and 28 days from DOC evaluation
|
Determination of the specificity of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
기간: 3 months
|
Determination of the negative predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
기간: 3 months
|
Determination of the positive predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to eyes-opening
기간: 3 months
|
Determination of the sensibility of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
기간: 3 months
|
Determination of the specificity of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Description of the amplitudes of the P3a wave to own-name uttered by expressive voices versus neutral voices.
기간: 3 months
|
Amplitudes of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
|
Description of the latencies of the P3a wave to own-name uttered by expressive voices versus neutral voices.
기간: 3 months
|
Latencies of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 2020-A00747-32
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .